AJCN EB Program 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenberg, J. A
Right arrow Articles by Geliebter, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenberg, J. A
Right arrow Articles by Geliebter, A.
Agricola
Right arrow Articles by Greenberg, J. A
Right arrow Articles by Geliebter, A.
American Journal of Clinical Nutrition, Vol. 84, No. 4, 682-693, October 2006
© 2006 American Society for Nutrition

REVIEW ARTICLE

Coffee, diabetes, and weight control1,2

James A Greenberg, Carol N Boozer and Allan Geliebter

1 From the Department of Health and Nutrition Sciences, Brooklyn College, City University of New York, New York NY (JAB), and the Department of Medicine, Columbia University and New York Obesity Research Center, St Luke's–Roosevelt Hospital Center, New York, NY (NB and AG)

2 Reprints not available. Address correspondence to JA Greenberg, Department of Health and Nutrition Sciences, Brooklyn College of the City University of New York, 2900 Bedford Avenue, Brooklyn, NY 11210. E-mail: jamesg{at}brooklyn.cuny.edu.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EPIDEMIOLOGIC STUDIES
 LABORATORY STUDIES
 OTHER HEALTH EFFECTS
 NONCAFFEINE COMPOUNDS IN COFFEE
 CONCLUSIONS
 REFERENCES
 
Several prospective epidemiologic studies over the past 4 y concluded that ingestion of caffeinated and decaffeinated coffee can reduce the risk of diabetes. This finding is at odds with the results of trials in humans showing that glucose tolerance is reduced shortly after ingestion of caffeine or caffeinated coffee and suggesting that coffee consumption could increase the risk of diabetes. This review discusses epidemiologic and laboratory studies of the effects of coffee and its constituents, with a focus on diabetes risk. Weight loss may be an explanatory factor, because one prospective epidemiologic study found that consumption of coffee was followed by lower diabetes risk but only in participants who had lost weight. A second such study found that both caffeine and coffee intakes were modestly and inversely associated with weight gain. It is possible that caffeine and other constituents of coffee, such as chlorogenic acid and quinides, are involved in causing weight loss. Caffeine and caffeinated coffee have been shown to acutely increase blood pressure and thereby to pose a health threat to persons with cardiovascular disease risk. One short-term study found that ground decaffeinated coffee did not increase blood pressure. Decaffeinated coffee, therefore, may be the type of coffee that can safely help persons decrease diabetes risk. However, the ability of decaffeinated coffee to achieve these effects is based on a limited number of studies, and the underlying biological mechanisms have yet to be elucidated.

Key Words: Coffee • caffeine • tea • diabetes • weight loss • glucose tolerance


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EPIDEMIOLOGIC STUDIES
 LABORATORY STUDIES
 OTHER HEALTH EFFECTS
 NONCAFFEINE COMPOUNDS IN COFFEE
 CONCLUSIONS
 REFERENCES
 
Coffee consumption, which probably originated in northeast Africa, spread throughout the Middle East in the 15th century and thence to Europe (1). It is estimated that more than half of the US population now consumes coffee (2). Of the 20 epidemiologic studies of coffee that were identified (3-22), 17 (3-19) found evidence that coffee consumption can reduce the risk of type 2 diabetes, improve indicators of normal glucose metabolism, or both (Table 1Go). It has been estimated that diabetes will afflict {approx}12% of Americans (23) and that 220 million cases of type 2 diabetes will exist worldwide by 2010 (24). The epidemiologic findings offer the promise that coffee, or one or more of its many constituents (25), may prove to be useful in the development of strategies for the prevention or treatment of diabetes.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Epidemiologic studies of habitual coffee consumption and diabetes risk1

 
This review discusses epidemiologic and laboratory studies of the effects of coffee and its constituents on diabetes risk. We focused on factors related to diabetes risk, such as weight loss and glucose metabolism. To provide an empirical basis for assessing the overall health effects of coffee consumption, we included studies of other health effects of coffee. Only studies published in peer-reviewed journals were considered. We first used MEDLINE to locate relevant studies published during the past decade. Reference lists in these studies were used to find relevant older studies. A summary of findings relevant to the possibility of using coffee or its constituents for diabetes prevention and suggestions for future research are included here.


   EPIDEMIOLOGIC STUDIES
TOP
 ABSTRACT
 INTRODUCTION
 EPIDEMIOLOGIC STUDIES
LABORATORY STUDIES
 OTHER HEALTH EFFECTS
 NONCAFFEINE COMPOUNDS IN COFFEE
 CONCLUSIONS
 REFERENCES
 
Only 3 (20-22) of the 20 identified published epidemiologic studies of the association between habitual coffee consumption and diabetes risk, healthy glucose metabolism, or both (3-22) did not find a protective effect, and none found a deleterious effect (Table 1Go). Eleven of the reported analyses were prospective cohort studies (3-11, 18, 19), one of which was a meta-analysis (9). Ten were cross-sectional studies (7, 12-17, 20-22). Seven found the protective effect to be dose-related (3-5, 7, 10, 11, 14). The 4 studies that tested decaffeinated coffee found a protective effect (5, 10, 11, 17), and 1 of those studies found the same results in 2 separate, large prospective cohorts (5). Four studies concluded that coffee constituents other than caffeine were involved in the protective effect (10, 11, 12, 17). One prospective study did not find a protective effect from instant coffee (10), but another study did find such an effect (11).

One study that assessed the effect of weight change found a prospective protective effect of beverage consumption that occurred only in participants who had previously lost weight (10). The protective effect occurred subsequent to the weight loss and was related to the weight loss in a dose-response manner, which suggested that the weight loss was the key. In addition, this study found that intakes of ground caffeinated and ground decaffeinated coffee were independently associated with the prior weight loss, which implies that both caffeine and noncaffeine compounds in coffee may help people decrease body weight. This idea is supported by the results of a recent, larger, prospective epidemiologic study, which found that increases in the intakes of caffeine, coffee, and decaffeinated coffee were inversely associated with weight gain over a 12-y period (26). However, the effects were relatively modest, which suggests that any weight loss caused by caffeine or coffee is unlikely to explain the negative association of either substance with diabetes risk.


   LABORATORY STUDIES
TOP
 ABSTRACT
 INTRODUCTION
 EPIDEMIOLOGIC STUDIES
 LABORATORY STUDIES
OTHER HEALTH EFFECTS
 NONCAFFEINE COMPOUNDS IN COFFEE
 CONCLUSIONS
 REFERENCES
 
Weight loss
Studies have shown that long-term consumption of caffeine (27-29), caffeinated cola (30), and caffeinated tea (31) decreases body weight in rodents. Some studies have also found decreases in adipose-pad weight (27-31) and the number of adipocytes (28), sometimes without a decrease in daily caloric intake (27, 30, 31). Bukowiecki et al (32) found that adding cola to an ad libitum Purina chow diet increased total energy intake by 50% and decreased the rate of body weight gain in rats.

These animal studies and the prospective epidemiologic studies on weight loss (11, 26) suggest that long-term caffeine and coffee consumption could decrease body weight in humans. There is little evidence from trials in humans, and the findings are equivocal. In one 24-wk placebo-controlled trial in humans, caffeine did not induce significant weight loss in obese subjects (33). It is possible that caffeine may induce significant weight loss in nonobese subjects because caffeine has been shown to cause greater thermogenesis, lipolysis, and fat oxidation (see Thermogenesis) and insulin secretion (see Insulin secretion) in nonobese than in obese persons. Kovacs et al (34) found no significant difference in weight regain during the 13 wk after a very-low-energy diet between participants who ingested caffeine in green tea and those who ingested placebo.

Noncaffeine compounds may also exist in coffee that induce weight loss, which could help explain the epidemiologic finding that increasing consumption of ground decaffeinated coffee was significantly associated with weight loss (10).

Research is needed on the possibility that long-term caffeine and coffee consumption can help reduce body weight in humans. Such weight reduction would probably decrease the risk of diabetes, because weight loss lowers diabetes risk (35).

Thermogenesis and lipid metabolism
Thermogenesis
Considerable evidence from studies in humans supports the hypothesis that coffee consumption induces weight loss by increasing thermogenesis. It has been estimated that a habitual consumption of 6 cups coffee (ie, 600 mg caffeine/d) causes an increase in energy expenditure (EE) of {approx}100 kcal/d (36), which could indeed lead to significant weight loss. This estimate does not apply equally to all types of coffee. EE has been found to be elevated for several hours after either injection of caffeine (30) or ingestion of caffeine (36-39), ground caffeinated coffee (40), or instant caffeinated coffee (41, 42). There is evidence that the increase in energy consumption is related to the dose of caffeine consumed (38, 39). In addition, 24-h EE has been found to be raised by the ingestion of caffeine (43) and instant-caffeinated coffee (44). Similarly, it has been shown that the thermic effect of food is increased by the ingestion of caffeine (36) and instant-caffeinated coffee (42, 44). The one study in human subjects of the consumption of decaffeinated coffee, in the form of ground decaffeinated coffee, did not find an increase thermogenesis (40).

This accumulated evidence from human studies suggests that caffeine is the primary, and possibly the sole, ingredient in coffee that is responsible for coffee's thermogenic effect, given that the one study of decaffeinated coffee and EE found no significant effect (40). On the other hand, the lack of a link between decaffeinated coffee consumption and EE is based on only one study. No studies of the influence of decaf-feinated coffee intake on the thermic effect of food have been conducted.

Tolerance does not appear to develop to caffeine's thermogenic response in persons who are regular coffee or tea drinkers, because Jung et al (37) found increases in thermogenesis in regular drinkers. Astrup et al (38) found the same result in subjects who had fasted overnight, which suggests that, if tolerance erodes with time, it takes >12 h to do so.

Lipid metabolism
Coffee may increase thermogenesis in part by increasing fat oxidation. In long-term rodent studies, caffeine ingestion reduces adipose-pad size (27-31) and the number of adipocytes (28). These findings suggest that caffeine and coffee consumption could help individuals lose weight by reducing body fat, possibly by increasing lipid metabolism. Using a lowered respiratory exchange ratio as an indicator of greater fat oxidation in human subjects, some investigators concluded that fat oxidation is increased in humans by consumption of caffeine (42, 45, 46) and caffeinated coffee (42, 44). Decaffeinated coffee was the placebo when caffeinated coffee was tested (42, 44), which suggests that it is the caffeine that induces the fat oxidation, although no one has yet compared the effects of decaffeinated coffee with the effects of a noncoffee, noncaffeine placebo.

Not all investigators have found that caffeine increases fat oxidation in human subjects. Dulloo et al (47) observed no significant change in the respiratory exchange ratio after ingestion of caffeine by healthy young male subjects, and Arciero et al (48) also found no such change in old and young adult male subjects.

Lipolysis
Lipolysis is another indicator of lipid metabolism, and greater lipolysis has frequently been observed after caffeine or coffee intake by human subjects. Investigators have used either plasma free fatty acids (FFA) and glycerol assays as indicators of lipolysis, and glycerol is considered the more reliable indicator (49). Several human studies found that an acute increase in lipolysis resulted from ingestion of caffeine (45, 46, 37, 50-52), ground caffeinated coffee (45) and instant caffeinated coffee (44, 50, 53, 54). No increase in lipolysis was found after ingestion of decaffeinated coffee (45), instant decaffeinated coffee (50) or ground decaffeinated coffee (55); these results derive from only one human study for each type of decaffeinated coffee.

Obesity
Some evidence exists that caffeine's ability to increase thermogenesis, fat oxidation, and lipolysis and thereby to help persons lose weight is greater in nonobese than in obese persons. Some (37, 42, 44), but not all (37), human studies found that caffeine increases thermogenesis more in nonobese than in obese subjects. Similarly, Acheson et al (42) and Daubresse et al (50) found that caffeine induced greater increases in lipolysis in nonobese than in obese subjects, and Acheson et al (42) found the same pattern for fat oxidation. In contrast, Bracco et al (44) did not find that caffeine ingestion increased fat oxidation more in nonobese than in obese female subjects. Acheson et al (42) suggested that the generally lower sensitivity to lipolytic stimuli observed in obese subjects than in nonobese subjects may be responsible for causing greater effects in nonobese subjects.

Biological mechanisms
The laboratory evidence presented above makes it seem likely that caffeine is the main ingredient that gives coffee its ability to induce weight loss, fat oxidation, lipolysis, and thermogenesis. However, the specific mechanisms by which caffeine induces these effects are not presently known. As pointed out by Graham (43), most of the evidence about such mechanisms is derived from animal or in vitro models. It is still not clear which specific mechanisms in which tissues in the intact animal are involved in caffeine's responses.

Astrup et al (38) conducted a study in humans that illustrates the possible links between caffeine intake, fat oxidation, lipolysis, thermogenesis, and weight loss. They measured EE, blood pressure, heart rate, and plasma hormone and substrate concentrations in response to caffeine intake in 6 healthy human subjects. Using regression techniques, they found that caffeine-induced changes in heart rate, plasma lactate, and plasma triacylglycerol responses accounted for 67% of the variation in the thermic effect of caffeine. It seems likely, therefore, that a sizeable portion of the thermogenic effect of caffeine may be due to increased cardiovascular work and to thermogenic processes associated with the production of lactate and triacylglycerol. The increase in cardiovascular work is probably due to caffeine's increasing the peripheral resistance (56), which raises blood pressure. The increase in lactate could involve the Cori cycle, in which glucose and glycogen are converted to lactate. As suggested by Astrup et al (38) and Graham (43), the association between thermogenesis and triacylglycerol concentrations may be due to the extra energy required for the increased reesterifaction involved in producing triacylglycerol. The increased reesterifaction is thought to take place in the liver and to be induced by increased hepatic uptake of FFA triggered by increases in plasma FFA due to caffeine intake. These ideas are consistent with studies showing that caffeine ingestion does not increase the energy cost of exercise in women (44).

Despite the multitude of studies that have investigated coffee and caffeine, there is still no clear, well-accepted understanding of their mechanisms of action. In a review of caffeine, Daly (54) concluded, "[I]t will undoubtedly be years before a satisfactory understanding of the complex mechanism of the action of caffeine is attained." It seems likely that the same is true of the many noncaffeine constituents of caffeine, which have not been researched as well as has caffeine.

Caffeinated coffee has been studied much more frequently than decaffeinated coffee, and caffeine appears to be responsible for some of the actions of caffeinated coffee. The 4 most popular mechanisms thought to underlie caffeine's effects are adenosine receptor antagonism; increased concentrations of catecholamines, particularly epinephrine; inhibition of cyclic nucleotide phosphodiesterases; and increased intracellular calcium. It seems unlikely that the last 2 mechanisms play an important role. For caffeine to act as a phosphodiesterase inhibitor or stimulator of calcium-release channels, pharmacologic or lethal concentrations (500–5000 µmol caffeine/L) are needed. These concentrations are an order of magnitude higher than concentrations achieved by normal coffee drinking—from 5 to 20 µmol caffeine/d (57). Moreover, according to Daly and Fredholm (58), caffeine is only a weak phosphodiesterase inhibitor, even at pharmacologic or lethal concentrations.

Caffeine has been shown to have many in vivo pharmacologic effects that are opposite to those of adenosine (59). It has also been found that the function of adenosine receptors is partially blocked by caffeine at plasma concentrations of 5–10 µmol/L. Caffeine is 1,3,7-trimethylxanthine, which is demethylated to 3 pharmacologically active dimethylxanthines after ingestion: theophylline, theobromine, and paraxanthine. Paraxanthine is the primary metabolite found in blood after caffeine ingestion (59). The structure of xanthines is similar to that of adenosine, which allows the xanthines to bind to and antagonize adenosine receptors. Methylxanthines, including caffeine, are widely used as antagonists for adenosine receptors (59), which are ubiquitous in the body. In rats, they occur in the nervous system, brain, vascular endothelium, heart, liver, kidney, adipose tissues, and muscle (60, 61).

Caffeine has been shown to cross the blood-brain barrier and to increase circulating concentrations of epinephrine in humans (62, 63), which suggests that some of caffeine's effects are modulated by sympathetic stimulation. For example, epinephrine is known to increase thermogenesis in humans, so it seems logical to attribute part of the caffeine-induced increase in thermogenesis (see Thermogenesis) to ß-andrenergic stimulation.

It is likely that adenosine-receptor antagonism (37) plays a part in caffeine's ability to increase lipolysis. Adenosine suppresses lipolysis in rats (64), and thus adenosine-receptor blockade by caffeine should increase lipolysis. In addition, good reasons exist to believe that elevated catecholamine concentrations mediate caffeine's effects on lipolysis in humans (52). Catecholamines have been found to be important regulators of lipolysis, and elevated concentrations of epinephrine have been found to elevate lipolysis in humans (65). Catecholamines and adenosine-receptor antagonism are thought to increase lipolysis by raising adipose tissue concentrations of cyclic AMP, which has been shown to increase cellular lipase and lipolysis in humans (53).

Some researchers assessed the relative importance of catecholamine elevation and adenosine-receptor antagonism in the relation between caffeine and lipolysis, and several investigators concluded that the major factor is increased epinephrine concentrations. Thong and Graham (52), for instance, found that caffeine-induced elevations in plasma FFA and glycerol in 7 healthy young men were eliminated by administration of a ß-adrenergic receptor blocker, propranolol. Keijzers and De Galan (51) found that an adenosine reuptake inhibitor, dypiramidole, which does not cross the blood-brain barrier, did not elevate epinephrine or plasma FFA in 12 healthy volunteers. In contrast, they found that caffeine, which is an adenosine-receptor antagonist and which does cross the blood-brain barrier where it can act to elevate epinephrine, elevated both epinephrine and plasma FFA.

Other investigators concluded that adenosine-receptor antagonism by caffeine accounts for caffeine's ability to induce lipolysis in humans. Jung et al (37), for instance, found in regular caffeine-beverage drinkers that caffeine ingestion or injection did not increase plasma concentrations of epinephrine but did increase plasma FFA and glycerol. Their conclusion was that it was not via the sympathoadrenal mechanisms that caffeine elevated plasma FFA and glycerol, because their subjects had developed tolerance to the ability of caffeine to elevate epinephrine. Their conclusion is supported by research showing that sympathetectomized animals have a normal response to caffeine (66). The mechanisms and pathways involved in caffeine's thermogenic and lipolytic effects have yet to be clarified.

Physical activity
Caffeine or coffee could also cause weight loss by inducing increases in physical activity. First, caffeine or other coffee compounds may stimulate a spontaneously higher rate of physical activity. Caffeine has been found to increase motor activity in rodents at doses between 3 and 30 mg/kg and to reduce motor activity at higher doses (55). Nonexercise activity thermogenesis was found to consume up to 350 kcal/d in humans (67), and Bracco et al (44) found that spontaneous physical activity did not increase in humans who drank 5 cups instant caffeinated coffee/d, as assessed by a radar motion-detection system. It is possible that the physical activity response is biphasic in humans, as it has been found to be in rodents, and that the caffeine dose used by Bracco et al was high enough to induce decreases in physical activity.

Second, there is abundant evidence that ingestion of caffeine by human subjects improves exercise performance (67), which could lead them to increase their level of physical activity. Caffeine, but not coffee, has been shown to have an ergogenic effect—ie, to increase endurance, speed, power output, or all 3—in human exercise activities lasting from 1 min to 2 h (43). This finding suggests that there are noncaffeine compounds in coffee that counteract the ergogenic effects of caffeine.

Glucose metabolism
Evidence in humans and rodents
The results of most studies of the acute effects of caffeine ingestion on glucose metabolism and insulin sensitivity, as measured by using an oral-glucose-tolerance test or hyperinsulinemic euglycemic or hypoglycemic clamp shortly after caffeine intake, are at odds with the epidemiologic study findings that long-term coffee consumption can increase insulin sensitivity and decrease diabetes risk. Lane et al (68) cautioned that the consumption of caffeinated beverages by persons with diabetes could increase the risk of diabetes complications. This finding is consistent with findings in most studies in humans that glucose metabolism is impaired shortly after the ingestion of caffeine (51, 68-72), ground caffeinated coffee (73), or instant caffeinated coffee (74-76). A minority of these studies have found no impairment in glucose metabolism after ingestion of caffeine (50) or instant caffeinated coffee (34, 38). It is interesting that many studies showed that ingestion of coffee or caffeine without inclusion of a carbohydrate meal does not lead to significant changes in plasma glucose or insulin concentrations (50, 52, 54, 68, 70, 71, 73).

Two human studies that distinguished between caffeinated and decaffeinated coffee suggest a possible resolution of the difference between caffeine's negative short-term effects on glucose metabolism and coffee's long-term ability to decrease diabetes risk. Naismith et al (77) found that consumption of decaffeinated coffee for 14 d decreased blood glucose in healthy volunteers accustomed to consuming 560 mg caffeine/d. They used a crossover design without randomization, and the 20 volunteers served as their own controls. Battram et al (73), using a similar design with randomization and 10 volunteers, found that the ingestion of caffeine increased plasma glucose and insulin more than did that of ground caffeinated coffee and also that the ingestion of ground caffeinated coffee increased plasma glucose more than did that of ground decaffeinated coffee, which actually decreased plasma glucose. The findings of Naismith et al and Battram et al suggest that there are noncaffeine compounds in coffee that counteract caffeine's acute impairment of glucose metabolism and hence contribute to the ability of long-term consumption of ground coffee to enhance glucose tolerance and insulin sensitivity. The findings of Battram et al also suggest that ground decaffeinated coffee has stronger potential than does ground caffeinated coffee to enhance insulin sensitivity and reduce diabetes risk over the long term.

It is possible that tolerance develops to caffeine's impairment of glucose metabolism, although no evidence of this exists as yet in humans (51). In a randomized controlled trial, van Dam et al (78) found that such tolerance did not develop in a period of 4 wk. Choi et al (30) found that rats fed caffeinated cola for 28 wk had insulin sensitivity significantly higher than that of controls, which suggested that such tolerance does develop in rats. Petrie et al (70) and Robinson et al (71) found evidence that, when tolerance does develop in humans, it is reversed by ≤48 h of abstinence.

Biological mechanisms
Current evidence suggests that caffeine induces a decrease in insulin sensitivity primarily by diminishing the glucose uptake in skeletal muscle. Caffeine ingestion has been shown to increase glucose uptake in the liver in dogs (79) and to decrease it in human skeletal muscle (80). It seems likely that, in humans, the decrease in skeletal muscle is larger than the increase in the liver because skeletal muscle comprises {approx}35–40% of the human body; skeletal muscle is responsible for 50–85% of glucose clearance after carbohydrate ingestion and infusion (81). Thong et al (80), using direct Fick techniques during an insulin clamp test, observed that human leg muscle glucose uptake was suppressed by {approx}50% after caffeine ingestion. Because caffeine is known to antagonize adenosine receptors, and adenosine is known to facilitate the action of insulin on the glucose uptake by adipocytes, it is possible that adenosine-receptor blockade is a key mechanism by which caffeine intake decreases insulin sensitivity (82).

Evidence suggests that caffeine acutely inhibits insulin sensitivity and glucose tolerance primarily by increasing epinephrine in humans. First, there are reports that caffeine increases circulating concentrations of epinephrine (51, 52, 63) and simultaneously decreases insulin sensitivity (51, 52) in human subjects. Second, some studies in humans showed that adrenalin activates the ß-adrenergic receptor and decreases insulin stimulation of whole-body glucose metabolism (83, 84). Third, reports exist that caffeine ingestion in humans with impaired epinephrine response has no effect on glucose or insulin concentrations (85). Fourth, Keijzers and De Galan (51) found that ingestion of caffeine by human subjects increased epinephrine and decreased insulin sensitivity, whereas ingestion of dipyridamole, an adenosine reuptake inhibitor, did not induce either of these changes. Fifth, Thong and Graham (52) found that insulin sensitivity in human subjects was reduced and plasma concentrations of insulin were increased when caffeine was administered alone but not when caffeine was administered together with propranolol, a nonselective ß-adrenergic receptor blocker.

Insulin secretion
Evidence suggests that caffeine induces acute increases in ß-cell insulin secretion that could be involved in the impairment of glucose tolerance and the decrease in insulin sensitivity brought on by caffeine. Thong and Graham (52) found that C-peptide, an indicator of insulin secretion, was elevated by 39% by ingestion of caffeine in a controlled trial involving an oral-glucose-tolerance test in healthy young men. Using a similar experimental design, Robinson et al (71) found evidence of a nonsignificant caffeine-induced increase in insulin secretion in men with type 2 diabetes, and Petrie et al (70) found no increase in such insulin secretion in obese men. Arnlov and Vessby (13), in a cross-sectional epidemiologic study of 946 elderly adults, found that concentrations of early insulin response in a hyperinsulinemic-euglycemic clamp, an indicator of insulin secretion, were not elevated in habitual coffee drinkers. Wu et al (17), also in a cross-sectional epidemiologic study, found that greater intakes of caffeinated coffee, decaffeinated coffee and caffeine were associated with lower fasting C-peptide concentrations in 2112 healthy female nurses. They concluded that coffee consumption was associated with decreased insulin secretion and stated that this finding was consistent with an association of coffee consumption with increased insulin sensitivity. Wu et al also found that the effect was significantly stronger in obese and overweight than in normal-weight nurses; this finding may be related to the finding of Petrie et al that caffeine acutely increased insulin secretion in normal-weight but not in obese subjects.

In vitro evidence exists that caffeine increases ß-cell insulin secretion. Shi (86) found this to be true by using mice islets, and Bruton et al (87) found the same effect in mice ß-cells. They also found evidence that this effect was due in part to sensitization of the ryanodine receptor by caffeine, rather than being solely due to the inhibition of cyclic AMP-phosphodiesterases. It is also of interest that Bruton et al found that caffeine stimulated insulin secretion only in the presence of high concentrations of glucose. This finding is consistent with the fact that most of the epidemiologic studies that assessed fasting and postload glucose concentrations found that habitual coffee consumption was associated with postload but not fasting glucose concentrations (7, 9, 12, 14-16).

Satiety
Conceivably, caffeine or other compounds in coffee may enhance satiety, and hence long-term consumption of caffeine or coffee may help persons lose weight. In fact, the finding by Westerterp-Plantenga et al (88) that satiety assessed in a cross-sectional survey of 76 human subjects was positively correlated with the subjects' reported habitual caffeine consumption. Kovacs et al (34) found higher satiety and lower leptin concentrations in habitual caffeine-beverage drinkers who reported higher daily caffeine intake. Zheng et al (27) found in mice that long-term caffeine intake decreased body-weight growth and intraperitoneal adipose-pad weight without changes in food intake. Apparently the caffeine increased satiety, because the animals were fed ad libitum. The possibility that coffee intake influences satiety has not been well researched in humans.


   OTHER HEALTH EFFECTS
TOP
 ABSTRACT
 INTRODUCTION
 EPIDEMIOLOGIC STUDIES
 LABORATORY STUDIES
 OTHER HEALTH EFFECTS
NONCAFFEINE COMPOUNDS IN COFFEE
 CONCLUSIONS
 REFERENCES
 
The pressor effect
Ingestion of caffeine and some types of coffee by humans has been shown to acutely increase blood pressure (51, 89, 90) and peripheral circulatory resistance (90), an effect referred to as the pressor effect. The pressor effect is important to the relation between coffee and diabetes for 2 reasons. First, the extra energy required for the pressor effect may contribute to the increased thermogenesis observed after ingestion of caffeine. And this increased thermogenesis may help persons lose weight and hence reduce diabetes risk. Thus, the pressor effect may contribute toward coffee's ability to decrease diabetes risk. Second, the pressor effect could increase the risk of cardiovascular disease (CVD) events, particularly in persons with hypertension or other CVD risk factors. Therefore, given the high prevalence of CVD risk factors in the US population, the pressor effect could substantially reduce the usefulness of coffee or its constituents in diabetes prevention or treatment.

The pressor effect is probably caused by caffeine because most investigators have found the pressor effect to occur after the ingestion of caffeine (51, 54, 89-97), ground caffeinated coffee (40), instant caffeinated coffee (56, 97), and caffeinated Italian coffee, ie, espresso (90). However, a few investigators found that caffeinated coffee did not induce the pressor effect. Noordzij et al (98) found that blood pressure increased more when the caffeine was ingested alone than when it was ingested in coffee. Bracco et al (44) found that ingestion of instant caffeinated coffee did not induce a significant pressor effect, and Horst et al (40) concluded that ground decaffeinated coffee did not induce a pressor effect.

Tolerance to the caffeine-induced pressor effect develops within 4 d (62). This tolerance is partial in that it reduces, but does not negate, the effect observed in subjects with no tolerance (92, 99). Attenuation of the pressor effect starts 20 h after the ingestion of caffeine (56, 100).

Other health effects
Coffee is generally considered safe when consumed in moderation (101). For example, the Canadian government's Guidelines to Healthy Eating recommend limiting caffeine intake to 400–450 mg/d, which would be the amount ingested in consuming approximately three 8-oz (237-mL) cups of brewed caffeinated coffee (102). However, the toxic compounds in coffee (103) could have negative effects in pregnant or breastfeeding women and in children. Caffeine at high concentrations has been found to be teratogenic in animal studies (104). Browne (105) concluded, on the basis of a review of epidemiologic studies, that the evidence was not adequate to ascertain the possibility of risk of congenital abnormalities resulting from maternal caffeine consumption. Caffeine has been found to potentiate the teratogenic effect of other substances, such as tobacco and alcohol (106). Whereas the effects of coffee on infertility and prematurity have not been established, it does appear that ingestion of > 3 cups/d decreases fetal birth weight (107, 108). The Canadian guidelines recommend limiting caffeine consumption to 300 mg/d in pregnant and breastfeeding women, and to 85, 62.5, and 45 mg/d in children aged 10–12, 7–9, and 4–6 y, respectively (102).

Dependency on caffeine is characterized by the development of tolerance, as reflected by increases in dose size with time, persistent desire, and withdrawal symptoms (43). High doses can cause anxiety, nervousness, sleep disturbance, irritability, agitation, and gastrointestinal disturbances (109). Withdrawal symptoms include headaches, irritability, anxiety, depression, drowsiness, and fatigue.

Evidence shows that caffeine may have some deleterious effects in the elderly, such as increasing the risk of kidney stones (110). However, a large prospective epidemiologic study involving middle-aged women concluded that daily consumption of 8 oz caffeinated coffee, decaffeinated coffee, or tea was independently associated with a small (8–10%) reduction in the risk of kidney stone formation (111). Caffeine may also contribute to osteoporosis, because it increases urinary concentrations of calcium, and the resulting negative effects on calcium metabolism and bone grow with increasing age (110). Rapuri et al (112), for instance, found that the intake of > 18 oz coffee/d was associated with accelerated spinal bone loss in elderly postmenopausal women, and Hasling et al (113) found that > 29.5 oz coffee/d could induce a loss of an additional 1.6 mmol Ca/d in postmenopausal osteoporotic women. Harris and Dawson-Hughes (114) found that higher coffee intake accelerated bone loss in healthy postmenopausal women but only in those women whose calcium intake was below the recommended daily allowance of 800 mg.

As summarized above (see Evidence in humans and rodents), strong evidence exists that caffeine and caffeinated coffee decrease insulin sensitivity shortly after ingestion in humans. This hazard may be more likely in obese than in nonobese persons because caffeine reduces insulin sensitivity more in obese than in lean subjects (115). It may also be hazardous for patients with diabetes, because a caffeine-induced decrease in insulin sensitivity has been found in persons with type 2 (40) and type 1 (116) diabetes.

Several investigators found an epidemiologic association between coffee consumption and the elevation of serum lipids in Nordic countries in the 1980s, as discussed by James (117). Subsequent research showed that it is only boiled coffee, which was commonly consumed in the Nordic countries in the 1980s, that elevates serum lipids. Filtered coffee, which is the most common type of brewed coffee consumed in the United States, does not affect serum lipid concentrations (1).

Although caffeine has exhibited mutagenic potential in in vitro studies, researchers have found that caffeine has little, if any, carcinogenic potential in humans (118). To date, most human studies have been epidemiologic, and they suggest a weak potential for inducing bladder and pancreatic cancer and a weak protective effect for colon cancer (118). A large body of epidemiologic and laboratory evidence suggests that caffeine protects dopaminergic neurons and thereby may help prevent the onset of Parkinsonism (119). Caffeine has been used for a number of therapeutic purposes, eg, in bronchial asthma, as a cardiac stimulant, and as a diuretic (59).


   NONCAFFEINE COMPOUNDS IN COFFEE
TOP
 ABSTRACT
 INTRODUCTION
 EPIDEMIOLOGIC STUDIES
 LABORATORY STUDIES
 OTHER HEALTH EFFECTS
 NONCAFFEINE COMPOUNDS IN COFFEE
CONCLUSIONS
 REFERENCES
 
A relatively small, but increasing, amount of research has been done on the effects of noncaffeine constituents in coffee. Various studies suggest that such constituents could induce some of the effects in this review. Graham et al (120) found that caffeine, but not caffeinated coffee, was effective as an ergogenic aid in humans. They concluded that a noncaffeine constituent of coffee was involved and cited the discovery by Tse (121) of a substance in coffee that appeared to lower blood pressure and heart rate. The finding of Graham et al is relevant here because ergogenic potential—ie, the potential for physical work—could be associated with thermogenesis, lipolysis, fat oxidation, glucose metabolism, and the pressor effect.

Several studies have identified specific noncaffeine compounds that could affect diabetes risk. Johnston et al (74) reported that 5-caffeoxylquinic acid, the major chlorogenic acid in coffee, may help explain coffee's ability to decrease diabetes risk in human subjects. They found that the ingestion of either caffeinated or decaffeinated coffee containing equal amounts of chlorogenic acid and glucose caused acute changes in gastrointestinal hormone concentrations. They concluded that chlorogenic acid attenuated the rate of glucose uptake in the proximal small intestine and moved it to more distal regions of the small intestine. Their findings suggest that chlorogenic acid or some other noncaffeine coffee constituents antagonizes caffeine's stimulation of glucose uptake in the small intestine. Using a sugar absorption test of intestinal permeability, Nieuwenhoven et al (122) found that the addition of caffeine to a sports drink expedited glucose uptake in the small bowel in 10 athletes. The implication is that chlorogenic acid slows the absorption of glucose from the gut, whereas caffeine accelerates it. Rodriguez de Sotillo and Hadley (123) found that 3 wk of intravenous infusion of chlorogenic acid significantly lowered the postprandial peak response to a glucose challenge in insulin-resistant Zucker rats. Chlorogenic acid may have other positive effects on glucose metabolism, including enhancing the antioxidant effects of coffee (124), decreasing glucose output in the liver (125), and helping preserve ß-cell function by promoting the synthesis of the homeodomain transcription factor IDX-1, which helps beta cells respond to increases in plasma glucose (126).

Shearer et al (127) found that a synthetic quinidine, 3,4-diferuloyl-1,5-quinide, which was representative of quinides found in coffee, enhanced glucose clearance and insulin action in rats. They found evidence that the effect was due not to increased skeletal muscle uptake but rather to decreased liver glucose production. Two groups of investigators have suggested that antioxidants in coffee may protect against insulin resistance (128, 129), and evidence also exists that coffee has a high antioxidant capacity, even higher than that of tea (130). Prasad et al (131) found that when secoisolariciresinol diglucoside, an antioxidant dietary lignan that occurs in coffee, was fed orally to rats for 24 d, the development of streptozotocin-induced diabetes was reduced by 75%.

Some investigators suggested that the magnesium in coffee may explain the ability of habitual coffee consumption to increase in insulin sensitivity (132). Long-term magnesium intake has been followed by a lower risk of type 2 diabetes (133).

A nonphenolic phytochemical constituent in coffee, trigonelline (N-methylnicotinic acid), has been found to have a hypoglycemic effect in rabbits and alloxan-diabetic rats. In a noncontrolled pilot study involving 10 diabetes patients, single doses of 500, 1000, and 2000 mg trigonelline had mixed effects on blood glucose (134).

It is not known whether tolerance develops to the effects of chlorogenic acid, quinides, antioxidants, magnesium, or other coffee compounds that have the ability to enhance insulin sensitivity. It may be that such tolerance does not develop, even though tolerance to caffeine's ability to depress insulin sensitivity does develop. If tolerance to the noncaffeine compounds does not develop, that could help explain the apparent contradiction between the long-term epidemiologic finding that coffee enhances glucose tolerance and the short-term finding that coffee impairs glucose tolerance.


   CONCLUSIONS
TOP
 ABSTRACT
 INTRODUCTION
 EPIDEMIOLOGIC STUDIES
 LABORATORY STUDIES
 OTHER HEALTH EFFECTS
 NONCAFFEINE COMPOUNDS IN COFFEE
 CONCLUSIONS
REFERENCES
 
Most of the prospective epidemiologic studies suggested that long-term consumption of coffee (3-17) and decaffeinated coffee (5, 10, 11, 17) can reduce the risk of diabetes. One of these studies found that the intakes of caffeinated coffee, decaffeinated coffee, and caffeine were independently associated with weight loss (10). Another found that increasing intakes of these beverages were associated inversely with weight gain, but the effects were modest (26). It seems possible that long-term coffee consumption may have a weak ability to help persons achieve weight loss, and that this weight loss may contribute toward reducing the risk of diabetes.

Two of caffeinated coffee's short-term effects could cause negative health effects. First, the pressor effect could trigger CVD events (see The pressor effect). Second, decreases in glucose tolerance and insulin sensitivity (see Glucose metabolism) could lead to poor glycemic control and elevated risk of sequellae from repeated bouts of poor short-term glycemic control. These sequellae could include neuropathy and diabetic retinopathy. This idea is speculative at this time, because no studies have yet assessed the development of such complications. A few studies show that the ingestion of decaffeinated coffee does not cause either of these effects, at least in the short term (40, 73, 77).

The epidemiologic finding of a potential reduction in diabetes risk due to habitual consumption of caffeinated coffee suggests that tolerance does develop to the short-term decrease in glucose tolerance and insulin sensitivity or that coffee contains noncaffeine constituents that enhance glucose tolerance and insulin sensitivity. The epidemiologic finding that the habitual consumption of decaffeinated coffee protects against diabetes risk (10, 11, 17) also suggests a role for coffee's noncaffeine constituents. Some preliminary evidence exists that coffee constituents such as chlorogenic acid (74) and quinides (128) enhance glucose tolerance and insulin sensitivity. The findings by Johnston et al (74) suggest that chlorogenic acid can help persons lose weight by attenuating the absorption of glucose from the small intestine. However, research on the short-term effects of decaffeinated coffee and the noncaffeine constituents of coffee is in the very early stages. The same is true of the long-term effects. Only one prospective study has assessed the role of weight loss (10). It found a dose-response positive association between weight loss and ground decaffeinated coffee and found that the protective effect was limited to participants with prior weight loss.

Some preliminary evidence suggests that coffee consumption may affect levels of satiety (34, 88) or physical activity (see Physical activity) or both in humans. As yet, no studies have been conducted on the effect of different types of coffee on satiety and physical activity—both of which could affect weight loss and diabetes risk.

In conclusion, some early evidence exists that decaffeinated coffee, one or more of the noncaffeine constituents in coffee, or both may be better suited for enhancing glucose tolerance and insulin sensitivity than is caffeinated coffee. More research is needed to elucidate both the short- and long-term effects of decaffeinated coffee and its constituents on diabetes risk.


   ACKNOWLEDGMENTS
 
We thank several anonymous journal reviewers for their constructive comments, which helped us make substantial improvements in the manuscript.

JG conceptualized the study and wrote the first draft of the manuscript. CB and AG contributed to the sections on weight loss, fat oxidation, lipolysis, physical activity, thermogenesis, glucose metabolism, satiety, obesity, and biological mechanisms and edited the manuscript. None of the authors had any personal or financial conflict of interest.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EPIDEMIOLOGIC STUDIES
 LABORATORY STUDIES
 OTHER HEALTH EFFECTS
 NONCAFFEINE COMPOUNDS IN COFFEE
 CONCLUSIONS
 REFERENCES
 

  1. D'Amicis A, Viani R. The consumption of coffee. In: Garattini S, ed. Caffeine, coffee and health. New York, NY: Raven Press, Ltd, 1993:1–16.
  2. Lundsberg LS. Caffeine consumption. In: Spiller GA, ed. Caffeine. Boca Raton, FL: CRC Press, 1998:199–224.
  3. van Dam RM, Feskens EJ. Coffee consumption and risk of type 2 diabetes mellitus. Lancet 2002;360:1477–8.[Medline]
  4. Tuomilehto J, Hu G, Bidel S, Lindstrom J, Jousilahti P. Coffee consumption and risk of type 2 diabetes mellitus among middle-aged Finnish men and women. JAMA 2004;291:1213–9.[Abstract/Free Full Text]
  5. Salazar-Martinez E, Willett WC, Ascherio A, et al. Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med 2004;140:1–8.[Abstract/Free Full Text]
  6. Rosengren A, Dotevall A, Wilhelmsen L, Thelle D, Johansson S. Coffee and incidence of diabetes in Swedish women: a prospective 18-year follow-up study. J Intern Med 2004;255:89–95.[Medline]
  7. van Dam RM, Dekker JM, Nijpels G, Stehouwer CDA, Bouter LM, Heine RJ. Coffee consumption and incidence of impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes: the Hoorn Study. Diabetologia 2004;47:2151–9.
  8. Carlsson S, Hammar N, Grill V, Kaprio J. Coffee consumption and risk of type 2 diabetes in Finnish twins. Int J Epidemiol 2004;33:616–7.[Free Full Text]
  9. van Dam RM, Hu FB. Coffee Consumption and risk of type 2 diabetes: a systematic review. JAMA 2005;294:97–104.[Abstract/Free Full Text]
  10. Greenberg JA, Axen KV, Schnoll R, Boozer CN. Coffee, tea and diabetes: the role of weight loss and caffeine. Int J Obes Relat Metab Disord 2005;29:1121–9.[Medline]
  11. van Dam RM, Willett WC, Manson JE, Hu FB. Coffee, caffeine, and risk of type 2 diabetes: a prospective cohort study in younger and middle-aged U.S. women. Diabetes Care 2006;29:398–403.[Abstract/Free Full Text]
  12. Isogawa A, Noda M, Takahashi Y, Kadowaki T, Tsugane S. Coffee consumption and risk of type 2 diabetes mellitus. Lancet 2003;361:703–4.[Medline]
  13. Arnlov J, Vessby B. Coffee consumption and insulin sensitivity. JAMA 2004;291:1199–201.[Free Full Text]
  14. Agardh EE, Carlsson S, Ahlbom A, et al. Coffee consumption, type 2 diabetes and impaired glucose tolerance in Swedish men and women. J Intern Med 2004;255:645–52.[Medline]
  15. Soriguer F, Rojo-Martinez G, Esteva de Antonio I. Coffee consumption and type 2 diabetes mellitus. Ann Intern Med 2004;141:321–2 (letter).[Free Full Text]
  16. Yamaji T, Mizoue T, Tabata S, et al. Coffee consumption and glucose tolerance status in middle-aged Japanese men. Diabetologia 2004;47:2145–51.[Medline]
  17. Wu T, Willett WC, Hankinson SE, Giovannucci E. Caffeinated coffee, decaffeinated coffee, and caffeine in relation to plasma C-peptide levels, a marker of insulin secretion, in U.S. women. Diabetes Care 2005;28:1390–6.[Abstract/Free Full Text]
  18. Faerch K, Lau C, Tetens I, et al. A statistical approach based on substitution of macronutrients provides additional information to models analyzing single dietary factors in relation to type 2 diabetes in Danish adults: the Inter99 study. J Nutr 2005;135:1177–82.[Abstract/Free Full Text]
  19. Bidel S, Hu G, Sundvall J, Kaprio J, Tuomilehto J. Effects of coffee consumption on glucose tolerance, serum glucose and insulin levels—a cross-sectional analysis. Horm Metab Res 2006;38:38–43.[Medline]
  20. Saremi A, Tulloch-Reid M, Knowler WC. Coffee consumption and the incidence of type 2 diabetes. Diabetes Care 2003;26:2211–2.[Free Full Text]
  21. Reunanen A, Heliovaara M, Aho K. Coffee consumption and risk of type 2 diabetes mellitus. Lancet 2003;36:702–3.
  22. Mackenzie T, Brooks B, O'Connor G. Beverage intake, diabetes, and glucose control of adults in America. Ann Epidemiol 2006 Jan 31; Epub ahead of print.
  23. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998;21:475–6.[Medline]
  24. King H, Aubert R, Herman W. Global burden of diabetes, 1995–2025. Prevalence, numerical estimates and projections. Diabetes Care 1998;21:1414–31.[Abstract]
  25. Spiller MA. The chemical components of coffee. In: Spiller GA, ed. Caffeine. Boca Raton, FL: CRC Press, 1998:97–161.
  26. Lopez-Garcia E, van Dam RM, Rajpathak S, Willett WC, Manson JE, Hu FB. Changes in caffeine intake and long-term weight change in men and women. Am J Clin Nutr 2006;83:674–80.[Abstract/Free Full Text]
  27. Zheng G, Sayam K, Okubo T, Juneja LR, Oguni I. Anti-obesity effects of three major components of green tea, catechins, caffeine and theanine, in mice. In Vivo 2004;18:55–62.[Abstract/Free Full Text]
  28. Cheung WT, Lee CM, Ng TB. Potentiation of the antioipolytic effect of 2-chloroadenosine after chronic caffeine treatment. Pharmacology 1988;36:331–9.[Medline]
  29. Muroyama K, Murosaki S, Yamamoto Y, Odaka H, Chung HC, Miyoshi M. Anti-obesity effects of a mixture of thiamin, arginine, caffeine, and citric acid in non-insulin dependent diabetic KK mice. Nutr Sci Vitaminol (Tokyo) 2003;49:56–63.
  30. Choi SB, Park CH, Park S. Effect of cola intake on insulin resistance in moderate fat-fed weaning male rats, J Nutr Biochem 2002;13:727–33.[Medline]
  31. Han LK, Takaku T, Li J, Kimura Y, Okuda H. Anti-obesity action of oolong tea. Int J Obes Relat Metab Disord 1999;23:98–105.[Medline]
  32. Bukowiecki LJ, Lupien J, Follea N, Jahjah L. Effects of sucrose, caffeine and cola beverages on obesity, cold resistance, and adipose tissue cellularity. Am J Physiol 1983;244:R500–7.[Medline]
  33. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord 1992;16:269–77.
  34. Kovacs EMR, Lejeune MPGM, Nijs I, Westerterp-Plantenga MS. Effects of green tea on weight maintenance after body-weight loss. Br J Nutr 2004;91:431–7.[Medline]
  35. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev 2005;(2):CD005270.
  36. Dulloo A, Geissler C, Horton T, Miller D. Normal cafeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. Am J Clin Nutr 1989;49:44–50.[Abstract/Free Full Text]
  37. Jung RT, Shetty PS, James WPT, Barrand MA, Callingham BA. Caffeine: its effects on catecholamines and metabolism in lean and obese subjects. Clin Sci 1981;60:527–35.[Medline]
  38. Astrup A, Toubro S, Cannon S, Hein P, Breum L, Madsen J. Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. Am J Clin Nutr 1990;51:759–67.[Abstract/Free Full Text]
  39. Haldi J, Bachmann G, Ensor C, Wynn W. The effects of various amounts of caffeine on the gaseous exchange and the respiratory quotient in man. J Nutr 1941;21:307–12.[Abstract/Free Full Text]
  40. Horst K, Willson RJ, Smith RG. The effect of coffee and decaffeinated coffee on oxygen consumption, pulse rate and blood pressure. J Pharmacol. Exp Therap 1936;58:294–304.[Abstract/Free Full Text]
  41. Hollands M, Cawthorne MA. A simple apparatus for comparative measurements of energy expenditure in human subjects: the thermic effect of caffeine. Am J Clin Nutr 1981;34:2291–4.[Abstract/Free Full Text]
  42. Acheson KJ, Zahorska-Markiewicz B, Anantharaman K, Jequier E. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. Am J Clin Nutr 1980;33:989–97.[Abstract/Free Full Text]
  43. Graham TE. Caffeine and exercise: metabolism, endurance and performance. Sports Med 2001;31:785–807.[Medline]
  44. Bracco D, Ferrarra JM, Arnaud MJ, Jequier E, Schutz Y. Effects of caffeine on energy metabolism, heart rate, and methylxanthine metabolism in lean and obese women. Am J Physiol 1995;269:E671–8.[Medline]
  45. Costill DL, Dalsky GP, Fink WJ. Effects of caffeine ingestion on metabolism and exercise performance. Med Sci Sports 1978;10:155–8.[Medline]
  46. Ryu S, Choi SK, Joung SS, Suh H, Cha YS, Lee S, Lim K. Caffeine as a lipolytic food component increases endurance performance in rats and athletes. J Nutr Sci Vitaminol (Tokyo) 2001;47:139–46.[Medline]
  47. Dulloo AG, Duret C, Rohrer D, et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-hr energy expenditure and fat oxidation in humans. Am J Clin Nutr 1999;70:1040–5.[Abstract/Free Full Text]
  48. Arciero PJ, Gardner AW, Calles-Escandon J, Benowitz NL, Poehlman ET. Effects of caffeine ingestion on NE kinetics, fat oxidation, and energy expenditure in younger and older men. Am J Physiol 1995;268(6 Pt 1):E1192–8.
  49. Jungas RL, Ball EG. Studies on the metabolism of adipose tissue. XII. The effects of insulin and epinephrine on free fatty acid and glycerol production in the presence and absence of glucose. Biochemistry 1963;2:383–8.
  50. Daubresse J-C, Luyckx A, Demey-Ponsart E, Franchimont R, Lefebvre P. Effects of coffee and caffeine on carbohydrate metabolism, free fatty acid, insulin, growth hormone and cortisol plasma levels in man. Acta Diabetol Lat 1973;10:1069–84.
  51. Keijzers GB, De Galan BE. Caffeine can decrease insulin sensitivity in humans. Diabetes Care 2002;25:364–9.[Abstract/Free Full Text]
  52. Thong FS, Graham TE. Caffeine-induced impairment of glucose tolerance is abolished by beta-adrenergic receptor blockade in humans, J Appl Physiol 2002;92:2347–52.[Abstract/Free Full Text]
  53. Bellet S, Kershbaum A, Finck EM. Response of free fatty acids to coffee and caffeine. Metabolism 1968;17:702–7.[Medline]
  54. Avogaro P, Capri C, Pais M, Cazzolato G. Plasma and urine cortisol behaviour and fat mobilization in man after coffee ingestion. Israel J Med Sci 1973;9:114–9.[Medline]
  55. Sawynok J, Yaksh TL. Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol Rev 1993;45:43–85.[Medline]
  56. Whitsett TL, Manion CV, Christensen HD. Cardiovascular effects of coffee and caffeine. Am J Cardiol 1984;53:918–22.[Medline]
  57. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51:83–133.[Abstract/Free Full Text]
  58. Daly JW, Fredholm BB. Mechanisms of action of caffeine on the nervous system. In: Nehlig A, ed. Coffee, tea, chocolate and the brain. Boca Raton, FL: CRC Press, 2004:1–12.
  59. Daly JW. Mechanism of action of caffeine. In: Garattini S, ed. Caffeine, coffee and health. New York, NY: Raven Press, Ltd, 1993:97–150.
  60. Reppert SM, Weaver DR, Stehle JH, Rivkees SA. Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. Mol Endocrinol 1991;5:1037–48.[Abstract/Free Full Text]
  61. Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 1996;118:1461–8.[Medline]
  62. Robertson D, Wade D, Workman R, Woosley RL, Oates JA. Tolerance to the humoral and hemodynamc effect of caffeine in man. J Clin Invest 1981;67:1111–7.[Medline]
  63. Benowitz NL, Jacob P III, Mayan H, Denaro C. Sympathomimetic effects of paraxanthine and caffeine in humans. Clin Pharmacol Ther 1995;58:684–91.[Medline]
  64. Fredholm BB. Effects of adenosine, adenosine analogues and drugs inhibiting adenosine inactivation of lipolysis in rat fat cells. Acta Physiol Scand 1978;102:191–8.[Medline]
  65. Rebuffe-Scrive M, Anderson B, Olbe L, Bjorntorp P. Metabolism of adipose tissue in intraabdominal depots in severly obese men and women. Metabolism 1990;39:1021–5.[Medline]
  66. Strubelt O. The influence of reserpin, propranolol and adrenal medullectomy on the hyperglycaemic actions of theophylline and caffeine. Arch Int Pharmacodynam 1969;179:215–24.
  67. Levine JA, Lanningham-Foster LM, McCrady SK, et al. Interindividual variation in posture allocation: possible role in human obesity. Science 2005;307:584–6.[Abstract/Free Full Text]
  68. Lane JD, Surwit RS, Barkauskas CE, Feinglos MN. Caffeine impairs glucose metabolism in type 2 diabetes. Diabetes Care 2004;27:2047–8.[Free Full Text]
  69. Greer F, Hudson R, Ross R, Graham T. Caffeine ingestion decreases glucose disposal during a hyperinsulinemic-euglycemic clamp in sedentary humans. Diabetes 2001;50:2349–54.[Abstract/Free Full Text]
  70. Petrie HJ, Chown SE, Belfie LM, et al. Caffeine ingestion increases the insulin response to an oral-glucose-tolerance test in obese men before and after weight loss. Am J Clin Nutr 2004;80:22–8.[Abstract/Free Full Text]
  71. Robinson LE, Savani S, Battram DS, McLaren DH, Sathasivam P, Graham TE. Caffeine ingestion before andoral glucose tolerance test impairs blood glucose management in men with type 2 diabetes. J Nutr 2004;134:2528–33.[Abstract/Free Full Text]
  72. Pizziol A, Tikhonoff V, Paleari CD, et al. Effects of caffeine on glucose tolerance: a placebo-controlled study. Eur J Clin Nutr 1998;52:846–9.[Medline]
  73. Battram DS, Arthur R, Weekes A, Graham T. The glucose intolerance induced by caffeinated coffee ingestion is less pronounced than that due to alkaloid caffeine in men. J Nutr 2006;136:1276–80.[Abstract/Free Full Text]
  74. Johnston KL, Clifford MN, Morgan LM. Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. Am J Clin Nutr 2003;78:728–33.[Abstract/Free Full Text]
  75. Wachmann A, Hattner RS, George B, Bernstein DS. Effects of decaffeinated and nondecaffeinated coffee ingestion on blood glucose and plasma radioimmuno-reactive insulin responses to rapid intravenous infusion of glucose in normal man. Metabolism 1970;19:539–46.[Medline]
  76. Jankelson OM, Beaser SB, Howard RM, Maher J. Effect of coffee on glucose tolerance and circulating insulin in men with maturity-onset diabetes. Lancet 1967;1:527–9.[Medline]
  77. Naismith DJ, Akinayanju PA, Szanto S, Yudkin J. The effect in volunteers of coffee and decaffeinated coffee on blood glucose, insulin, plasma lipids and some factors involved in blood clotting. Nutr Metabol 1970;12:144–51.
  78. van Dam RM, Pasman WJ, Verhoef P. Effects of coffee consumption on fasting blood glucose and insulin concentrations: randomized controlled trials in healthy volunteers. Diabetes Care 2004;27:2990–2.[Free Full Text]
  79. Pencek RR, Battram D, Shearer J, et al. Portal vein caffeine infusion enhances net hepatic glucose uptake during a glucose load in conscious dogs. J Nutr 2004;134:3042–6.[Abstract/Free Full Text]
  80. Thong FS, Derave W, Kiens B, et al. Caffeine-induced impairment of insulin action but not insulin signaling in human skeletal muscle is reduced by exercise. Diabetes 2002;51:583–90.[Abstract/Free Full Text]
  81. Brundin T, Branstrom R, Wahren J. Effects of oral vs. iv glucose administration on spanchic and extrasplanchnic O2 uptake and blood flow. Am J Physiol 1996;271:E496–504.[Medline]
  82. Wynne K, Stanley S, Bloom S. The gut and regulation of body weight. J Clin Endocrinol Metab 2004;89:2576–82.[Abstract/Free Full Text]
  83. Avogaro A, Toffolo G, Valerio A, Cobelli C. Epinephrine exerts opposite effects on peripheral glucose disposal and glucose-stimulated insulin secretion. Diabetes 1996;45:1373–8.[Abstract]
  84. Laaskso M, Edelman SV, Brechtel B, Baron AD. Effects of epinephrine on insulin-mediated glucose uptake in whole body and leg muscle in humans: role of blood flow. Am J Physiol Endocrinol Metab 1992;263:E199–204.[Abstract/Free Full Text]
  85. Van Soeren M, Mohr T, Kjaer M, Graham TE. Acute effects of caffeine ingestion at rest in humans with impaired epinephrine responses. J Appl Physiol 1996;80:999–1005.[Abstract/Free Full Text]
  86. Shi CL. The effects of caffeine and acetylcholine on glucose-stimulated insulin release from islet transplants in mice. Cell Transplant 1997;6:33–7.[Medline]
  87. Bruton JD, Lemmens R, Shi C, et al. Ryanodine receptors of pancreatic beta-cells mediate a distinct context-dependent signal for insulin secretion. FASEB J 2003;17:301–3. Epub 2002 Dec 3.[Abstract/Free Full Text]
  88. Westerterp-Plantenga MS, Lejeune MPGM, Kovacs EMR. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. Obes Res 2005;13:1195–204.[Medline]
  89. Robertson D, Forlich JC, Carr RK, et al. Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med 1978;298:181–6.[Abstract]
  90. Casiglia E, Bongiovi S, Paleari CD, et al. Haemodynamic effects of coffee and caffeine in normal volunteers: a placebo-controlled clinical study. J Intern Med 1991;229:501–4.[Medline]
  91. Christensen B, Mosdol A, Retterstol L, Landaas S, Thelle DS. Abstention from filtered coffee reduces the concentrations of plasma homocysteine and serum cholesterol—a randomized controlled trial. Am J Clin Nutr 2001;74:302–7.[Abstract/Free Full Text]
  92. Izzo JL, Ghosal A, Kwong T, et al. Age and prior caffeine use alter the cardiovascular and adrenomedullary responses to oral caffeine. Am J Cardiol 1983;52:769–73.[Medline]
  93. Onrot J, Goldberg MR, Biaggioni I, Hollister AS, Kincaid D, Robertson D. Hemodynamic and humoral effects of caffeine in autonomic failure: therapeutic implications for postprandial hypotension. N Engl J Med 1985;313:549–54.[Abstract]
  94. Lenders JWM, Morrie HLC, Smits P, Thien T. The effects of caffeine on the postprandial fall of blood pressure in the elderly. Age Ageing 1988;17:236–40.[Abstract/Free Full Text]
  95. Lipsitz LA, Hansen RWMM, Connelly CM, Kelly-Gagnon MM, Parker AJ. Haemodynamic and neurohumoral effects of caffeine in elderly patients with symptomatic postprandial hypotension: a double-blind, randomized, placebo-controlled study. Clin Sci 1994;87:259–67.[Medline]
  96. Del Rio G, Menozzi R, Zizzo G, et al. Increased cardiovascular response to caffeine in perimenopausal women before and during estrogen therapy. Eur J Endocrinol 1996;135:598–603.[Abstract/Free Full Text]
  97. Heseltine D, El-Jabri M, Ahmed F, Knox J. The effect of caffeine on postprandial blood pressure in the frail elderly. Postgrad Med J 1991;67:543–7.[Abstract/Free Full Text]
  98. Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J Hypertens 2005;23:921–8.[Medline]
  99. James JE. Is habitual coffeine use a preventable cardiovascular risk factor? Lancet 1997;349:279–81.[Medline]
  100. Shi J, Benowitz NI, Denaro CP, Sheiner LB. Pharmacokinetic-pharmacodymanic modeling of caffeine: tolerance to pressor effects. Clin Pharmacol Ther 1993;53:6–14.[Medline]
  101. Garattini S. Overview. In: Garattini S, ed. Caffeine, coffee and health. New York, NY: Raven Press, Ltd, 1993:399–403.
  102. Health Canada Food Program. Fact sheet—it's your health: caffeine. Ottawa, Canada: Health Canada, 2006. Internet: http://www.hc-sc.gc.ca/food-aliment/dg/e_caffeine.html (accessed 26 July 2006).
  103. Viani R. The composition of coffee. In: Garattini S, ed. Caffeine, coffee and health. New York, NY: Raven Press, Ltd, 1993:17–41.
  104. Christian MS, Brent RL. Teratogen update: evaluation of the reproductive and developmental risks of caffeine. Teratology 2001;64:51–78.[Medline]
  105. Browne ML. Maternal exposure to caffeine and risk of congenital anomalies: a systematic review. Epidemiology 2006;17:324–31.[Medline]
  106. Nehlig A, Debry G. Potential teratogenic and neurodevelopmental consequences of coffee and caffeine exposure: a review on human and animal data. Neurotoxicol Teratol 1994;16:531–43.[Medline]
  107. Etherton GM, Kochar MS. Coffee. Facts and controversies. Arch Fam Med 1993;2:317–22.[Abstract/Free Full Text]
  108. Narod SA, De Sanjose S, Victora C. Coffee during pregnancy: a reproductive hazard? Am J Obstet Gynecol 1991;164:1109–14.[Medline]
  109. Smith BD, Tola K. Caffeine: effects on psychological functioning and Performance. In: Spiller GA, ed. Caffeine. Boca Raton, FL: CRC Press, 1998:278–9.
  110. Massey LK. Caffeine and the elderly. Drugs Aging 1998;13:43–50.[Medline]
  111. Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Beverage use and risk for kidney stones in women. Ann Intern Med 1998;128:534–40.[Abstract/Free Full Text]
  112. Rapuri PB, Gallagher JC, Kinyamu HK, Ryschon KL. Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr 2001;74:694–700.[Abstract/Free Full Text]
  113. Hasling C, Sondergaard K, Charles P, Mosekilde L. Calcium metabolism in postmenopausal osteoporotic women is determined by dietary calcium and coffee intake. J Nutr 1992;122:1119–26.[Abstract/Free Full Text]
  114. Harris SS, Dawson-Hughes B. Caffeine and bone loss in healthy postmenopausal women. Am J Clin Nutr 1994;60:573–8.[Abstract/Free Full Text]
  115. Chown S. Caffeine increases the insulin/glucose response to an OGTT in obese and lean males. Doctoral dissertation. University of Guelph, Guelph, Canada, 2001.
  116. de Galan BE, Tack CJ, Lenders JW, et al. Theophylline improves hypoglycemia unawareness in type 1 diabetes. Diabetes 2002;51:790–6.[Abstract/Free Full Text]
  117. James JE. Caffeine and cardiovascular health. In: Understanding caffeine: a biobehavioral analysis. London, United Kingdom: Sage Publication, 1997:80–102.
  118. James JE. Caffeine and cancer. In: Understanding caffeine: a behavioral analysis. London, United Kingdom: Sage Publications, 1997:103–15.
  119. Schwartzschild MA, Ascherio A. Caffeine and Parkinson's disease. In: Nehlig A, ed. Coffee, tea, chocolate, and the brain. Boca Raton, FL: CRC Press, 2004:147–59.
  120. Graham TE, Hibbert E, Sathasivam P. Metabolic and exercise endurance effects of coffee and caffeine ingestion. J Appl Physiol 1998;85:883–9.[Abstract/Free Full Text]
  121. Tse SYH. Cholinomimetic compound: distinct from caffeine contained in coffee. II: muscarinic actions. J Pharm Sci 1992;81:449–52.[Medline]
  122. Nieuwenhoven MA, Brummer RJM, Brouns F. Gastrointestinal function during exercise: comparison of water, sports drink and sports drink with caffeine. J Appl Physiol 2000;89:1079–85.[Abstract/Free Full Text]
  123. Rodriguez de Sotillo DV, Hadley M. Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats. J Nutr Biochem 2002;13:717–26.[Medline]
  124. Clifford MN. Chlorogenic acid and other cinnamates—nature, occurrence, dietary burden, absorption and metabolism. J Sci Food Agric 2000;80:1033–43.
  125. Arion WJ, Canfield WK, Ramos FC, et al. Chlorogenic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6-phosphatase. Arch Biochem Biophys 1997;339:315–22.[Medline]
  126. McCarty MF. A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk. Med Hypoth 2004;64:848–53.
  127. Shearer J, Farah A, de Paulis R, et al. Quinides of roasted coffee enhance insulin action in conscious rats. J Nutr 2003;133:3529–32.[Abstract/Free Full Text]
  128. Natella R, Nardini M, Giannetti I, Dattile C, Scaccini C. Coffee drinking influences plasma antioxidant capacity in humans. J Agric Food Chem 2002;50:6211–6.[Medline]
  129. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative-stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003;51:1–8.
  130. Svilaas A, Sakhi AK, Andersen LF, et al. Intakes of antioxidants in coffee, wine, and vegetables are correlated with plasma carotenoids in humans. J Nutr 2004;134:562–7.[Abstract/Free Full Text]
  131. Prasad K, Mantha SV, Muir AD, Westcott ND. Protective effect of secoisolariciresinol diglucoside against streptozotocin-induced diabetes and its mechanism. Mol Cell Biochem 2000;206:141–9.[Medline]
  132. Rodriguez-Moran M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 2003;26:1147–52.[Abstract/Free Full Text]
  133. Lopez-Ridaura R, Willett WC, Rimm EB, et al. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 2004;27:134–40.[Abstract/Free Full Text]
  134. Mishinsky J, Joseph B, Sulman FG. Hypoglycaemic effect of trigonelline. Lancet 1967;16:1311–2.
Received for publication December 2, 2005. Accepted for publication April 28, 2006.




This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
A. O Odegaard, M. A Pereira, W.-P. Koh, K. Arakawa, H.-P. Lee, and M. C Yu
Coffee, tea, and incident type 2 diabetes: the Singapore Chinese Health Study
Am. J. Clinical Nutrition, October 1, 2008; 88(4): 979 - 985.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenberg, J. A
Right arrow Articles by Geliebter, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenberg, J. A
Right arrow Articles by Geliebter, A.
Agricola
Right arrow Articles by Greenberg, J. A
Right arrow Articles by Geliebter, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS